Drug Discovery

#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

Webinar: How targeted proteomics supports different stages of drug development

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. The webinar, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘ is now available to watch on-demand. This webinar, hosted by DDW and… Read More

Webinar date:
Supported by Evotec
#News

Microbiome
#Clinical trials #Drug discovery #Irritable Bowel Syndrome #Microbiome

EnteroBiotix announces positive results for IBS microbiome therapy  

Biopharmaceutical company EnteroBiotix has announced positive final results from its  TrIuMPH clinical trial, which is evaluating the company’s full-spectrum microbiome therapeutic for patients with irritable bowel syndrome with constipation (IBS-C) with constipation or diarrhoea (IBS-D).  The Phase IIa clinical trial included 122 UK patients and results show that EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score (IBS-SSS) versus placebo. Read More

#News

#Automation / robotics #Events #Lab technology #SLAS2026

Expert in pharma lab automation solutions joins DDW at SLAS2026

James Pena, Director, Product Management – Digital Science & Automation Solutions, Thermo Fisher Scientific, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. He will present: From Data to Decisions: Digital-Ready Laboratories Powered by Automation. Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

Webinar: Where is AI delivering measurable gains for drug discovery?

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#News

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Uncover novel biomarkers using metabolomic and lipidomic profiling

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

3d structure of the protein molecule
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: A deep dive into high-throughput protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

#AI #Bayer #Cradle #Drug discovery

Bayer partners with Cradle to advance AI-led drug discovery 

Pharma giant Bayer has signed a three-year strategic collaboration with biotech company Cradle to advance AI-enabled antibody discovery and optimisation.  Bayer aims to implement Cradle’s AI software platform, used for protein engineering, to scale its drug discovery and development efforts. The company intends to integrate Cradle’s platform… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

How are companies translating AI into real scientific impact?

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#News

Cancer cell
#Cancer #Drug development #ESMO #Liver disease #Oncology

Autotaxin inhibition: unlocking new frontiers in cancers and beyond 

Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies.  Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF)… Read More

#Exclusive Content

#Clarivate #Drug discovery

Clarivate’s Drugs to Watch could ‘transform care’ 

Analytics company Clarivate has released its 2026 Drugs to Watch report, with eleven therapies expected to deliver clinical and commercial impact this coming year.  The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve… Read More

#News

3D protein molecules structure
#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

Webinar: Practical applications of MS-based targeted proteomics

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. Registrations are now open for a new webinar taking place on 29 January 2026, entitled ‘MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases‘. Read More

Webinar date:
Supported by Evotec
#News

#Automation / robotics #Events #Lab technology #SLAS2026

Discover what is revolutionising drug discovery with DDW at SLAS2026

Dr Preeti Ashok, Head of Cell Biology (Novoheart), Medera, will be speaking at the DDW track Creating Cures: The role of lab automation in successful drug discovery at SLAS2026. She will present:  From Animal Models to Human Mini-Hearts: How Automated Human-Based Testing is Revolutionising Drug Discovery. Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

Webinar: The power shift shaping biotech’s AI future

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#News

#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Precision medicine #Webinar

Webinar: The importance of untargeted approaches to discovery

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar begins with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#News

Lab equipment
#Assays #Biotech #Digital workflow #Drug discovery #Protein #Protein chemistry / Proteomics #Webinar

Webinar: Achieve high-throughput, multiplexed protein analysis

In this webinar, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in a single… Read More

#News

#AI #Cell and gene therapy #Charles River #Drug discovery #European Commission #European Union #FDA #Immune cells #Korea #Obesity #Personalised medicine #Rare disease #Regulatory

DDW Highlights: 23 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a research team found that a hidden molecular switch fuels obesity. Elsewhere, AI-generated… Read More

#Podcasts